PRO DEX INC (PDEX) received a Rule 144 notice from its Chief Financial Officer, Alisha Charlton, covering a proposed sale of 2,300 shares of common stock through Charles Schwab.
The notice reports an aggregate market value of $168,843 for these shares, based on the NASDAQ Capital Market closing price on September 4, 2026, with an approximate sale date of September 9, 2026 and 3,203,334 shares outstanding.
PRO DEX INC (PDEX) reported strong results for the fourth quarter and fiscal year ended June 30, 2026. Q4 net sales rose to $20.4 million, up 17% from $17.5 million, driven primarily by higher volumes of its largest customer’s next generation orthopedic handpiece. Q4 gross profit more than doubled to $7.1 million, lifting gross margin to 35% from 20%, while operating income increased to $3.5 million and net income to $2.9 million, or $0.87 per diluted share.
For fiscal 2026, net sales grew 16% to $77.5 million, gross profit increased 25% to $24.3 million, and gross margin improved to 31% from 29%. Operating income rose 22% to $13.0 million, and net income reached $13.7 million, or $4.12 per diluted share, aided by $5.7 million of gains on marketable equity investments. The acquisition of Advanced Precision Machining, LLC contributed additional revenue and higher margins but also added consulting and operating costs. Cash and cash equivalents increased to $8.2 million, while total notes payable rose to about $17.5 million.
Pro-Dex, Inc. (PDEX) reported strong growth for the year ended June 30, 2026, with net sales of $77.5 million, up 16% from 2025, and net income of $13.7 million, up from $9.0 million. Gross margin improved to 31%, and operating income rose to $13.0 million (17% of sales).
Growth was driven by a 30% increase in medical device revenue to $62.1 million, particularly orthopedic products for its largest customer following a next‑generation handpiece launch, while repair revenue declined 33% to $12.5 million as that customer transitioned away from legacy devices. Pro-Dex acquired Advanced Precision Machining, LLC (APM) in February 2026, adding aerospace and defense machining capabilities and contributing to a 76% increase in industrial and scientific sales. Other income benefited from realized gains on the Monogram investment, and the company generated $7.2 million of operating cash flow, ending the year with $8.2 million in cash and $40.3 million of working capital. Backlog was $32.9 million, down from $50.4 million, with most expected to ship in fiscal 2027. The company repurchased 79,898 shares for $3.4 million and had 3,203,334 shares outstanding as of September 2, 2026.
PRO DEX INC (PDEX) reported a compensation decision for senior management. On August 26, 2026, the Compensation Committee approved a $60,000 discretionary cash bonus for Chief Financial Officer Alisha K. Charlton and a $140,000 discretionary cash bonus for Chief Executive Officer Richard L. Van Kirk.
The company states that Mr. Van Kirk’s bonus was based on sales growth and fiscal 2026 financial performance exceeding plan. Both bonuses will be paid in cash in the next bi-weekly pay period, with a pay date of September 3, 2026. No other material corporate actions are described.
Pro Dex Inc director Angelita Rebamontan acquired 19 shares of common stock on July 23, 2026 at $33.25 per share through an Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c) and Rule 16b-3(d). After this acquisition, she directly holds 18,798 shares.
Pro-Dex Inc director Domingo Angelita Rebamontan reported an open-market sale of 998 shares of Common Stock on March 16, 2026, at $47.2400 per share. Following this transaction, the director directly holds 18,779 shares of Pro-Dex common stock.
PRO DEX INC Chief Financial Officer Alisha Charlton reported equity compensation activity rather than open-market trading. She received 10,800 shares of common stock at a stated price of $0.00 per share under a performance award agreement. On the same date, 3,897 shares were withheld at $62.74 per share to cover her tax obligations. After these transactions, she directly holds 24,170 shares of PRO DEX INC common stock.
PRO DEX INC director Angelita Rebamontan reported routine equity compensation activity. On a grant/award basis, she acquired 6,800 shares of Common Stock at $0.00 per share under a performance award agreement pursuant to the Pro-Dex, Inc. 2016 Equity Incentive Plan.
On the same date, 2,488 shares were disposed of at $62.74 per share to satisfy her tax withholding obligations, a non-market tax-withholding transaction. After these entries, she directly holds 19,777 shares of Common Stock.
PRO DEX INC Chief Executive Officer Richard Lee Van Kirk Jr reported compensation-related stock transactions. He received 14,800 shares of Common Stock as a grant under a performance award agreement pursuant to the Pro-Dex, Inc. 2016 Equity Incentive Plan. To cover tax obligations, 5,279 shares were withheld, which is recorded as a tax-withholding disposition rather than an open-market sale. Following these transactions, he directly holds 99,228 shares of PRO DEX INC common stock.
AO Partners Group and Nicholas J. Swenson filed an amended Schedule 13D disclosing a large ownership stake in Pro-Dex, Inc. common stock. Swenson beneficially owns 1,017,817 shares, representing 31.88% of the 3,192,759 shares outstanding as of April 30, 2026, through AO Partners I, L.P., AO Partners, LLC, Groveland DST LLC, and personal holdings.
The group acquired shares in open market purchases using $2,032,015 of AO Partners Fund working capital and Swenson’s personal capital because it believes Pro-Dex stock is undervalued and intends to influence company policies and assert shareholder rights to maximize value. AO Partners Fund has 922,204 shares and Groveland DST 34,316 shares; Swenson holds 61,297 shares directly.
The filing notes that AO Partners Fund has pledged 922,204 shares and Swenson has pledged 61,170 shares as collateral for bank loans obtained in the ordinary course of business. The group indicates it may buy more or sell shares in the future and acknowledges that its actions may constitute a control purpose under securities regulations.